What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors
JAMA · 03.03.2026 · 335 (9) · 749
DOI: 10.1001/jama.2026.0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 03.03.2026. Verfasst von Versha Pleasant und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
This Viewpoint discusses the benefits and risks of systemic hormone therapy in breast cancer survivors following the US Food and Drug Administration’s removal of black box warnings from menopausal hormone therapy.
Autor:innen und Institutionen
- Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor.
- Department of Obstetrics and Gynecology, University of Virginia, Charlottesville.
Förderung
- NIMHD NIH HHS
Zitieren
APA
Pleasant, V., & Ring, K. (2026). What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. JAMA, 335(9), 749. https://doi.org/10.1001/jama.2026.0025
Vancouver
Pleasant V, Ring K. What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. JAMA. 2026;335(9):749. doi:10.1001/jama.2026.0025
BibTeX
@article{Pleasant2026,
author = {Pleasant, Versha and Ring, Kari},
title = {What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors},
journal = {JAMA},
year = {2026},
volume = {335},
number = {9},
pages = {749},
doi = {10.1001/jama.2026.0025}
}
EUVIMED